摘要
目的评价吡柔比星膀胱灌注预防浅表性膀胱癌术后复发的疗效和安全性。方法将68例浅表性膀胱癌术后患者随机分为2个组，一组患者膀胱灌注羟基喜树碱（HCPT）32例，另一组膀胱灌注吡柔比星（THP）36例，随访6～24个月，观察两纽复发情况及不良反应。结果THP组2年复发率为13．9％，不良反应发生率为63．9％；HCPT组2年复发率为25．0％，不良反应发生率59．4％，比较两组复发率差异有统计学意义（P〈0．05），而两组不良反应发生率差异无统计学意义（P〉0．05）。结论膀胱灌注吡柔比星预防浅表性膀胱癌术后复发的疗效确切，不良反应小，患者耐受性好，是较为理想的膀胱灌注化疗药物。
Objective To evaluate the effect of pirarubicin（THP） by bladder instillation for preventing the superficial bladder cancer recurrence. Methods This study included 68 patients randomized to two groups. THP by bladder instillation was used in the first group（36 patients）, HCPT in the second group（32 patients）. They were followed up for 6-24 months. The recurrence and side effects were observed and compared between them. Results The recurrence rate in the THP group was 13.9% and that in the HCPT group was 25.0 %, there was significant difference between them（P〈0.05）. But there was no significant difference between two groups in the side effects（P〉0.05）. Conclusion Our study proved the effect of THP by bladder instillation for preventing the superficial bladder cancer recurrence is evident. THP is relatively ideal intravesical chemotherapeutic drug in prevention of the recurrence of bladder cancer,which is well tolerated by patients.
出处
《重庆医学》
CAS
CSCD
北大核心
2009年第17期2163-2164,共2页
Chongqing medicine
作者简介
通讯作者，电话：023-89011122；E-mail：wuxiaohou80@hotmail．com。
